Next Phase Newsletter

A venture arm of an innovation hub headquartered in California for life science, medtech, and technology companies invests in Pre-Seed and Seed stage biotech, device, and ag-tech companies in the U.S. The firm acts as a lead investor. For Pre-Seed rounds, typical check size falls between $250k-1M and for Seed rounds, typical check size falls between $1M-3M. For their main fund, it is not required for companies to go through the accelerator program, however the resources are available and encouraged 

In terms of life sciences and healthcare, the firm is interested in biotech and medical devices. For biotech, the firm is subsector agnostic, including drug development and bio tools, for device, the firm is open to all classes. The firm is also indication-agnostic. The firm typically looks at companies in pre-clinical stages. 

The firm requires companies to already be incorporated and have their CEOs to be fulltime. The firm may take a board seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A manufacturing company has a wide range of businesses including analytical instruments, medical devices, and industrial equipment. Recently, the company has been focusing on healthcare, specifically in clinical diagnostics and biomanufacturing. In April 2023, the company established a CVC (corporate venture capital) department and is looking for strategic partnerships with companies with cutting-edge technology that align with their businesses. The fund will be managed for 10 years with a total investment of $50M USD. So far, the venture arm has invested in 3 companies in the U.S. and Japan and is looking to expand their investments in the States, though they are open to meeting with global companies. The fund is looking to invest in Pre-Seed to Early rounds but may invest as far as Series A. Typical check size can range from $1-10M USD but can exceed if there is a particularly strong interest in a technology. 

In terms of healthcare, the venture arm is looking to invest in clinical diagnostics, medical devices, and biomanufacturing. The firm is open to not only hardware but consumables as well.  

To attract investment from the venture arm, having a lead investor is desirable. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A VC fund based in the U.S. invests in early-stage applied AI companies in healthcare, enterprise, and automation. The firm follows their thesis of partnering and investing in entrepreneurs who have a deep desire to use AI-enabled technology to tackle the most challenging problems in the given industries. The founder, a tech entrepreneur themself, started the fund with the idea of wanting to pay it forward towards startups that can make a large impact in the world. The firm can invest in Seed to Series B rounds with check size ranging from $250k-4M USD. The firm focuses on companies in the U.S., Canada, and the U.K. The firm can lead investments as they like to be active investors, utilizing their strong network to help companies with operations, funding, commercialization, and more. 

In terms of healthcare, the firm invests in companies that blend technology toward healthcare applications; what the firm likes to call “tech-bio”. Some examples include technology that can improve how drugs are discovered, targeted and delivered, that drive clinical results with biased-free patient selection and data transparency, digital therapeutics, and precision medicine. The goal is to improve patient outcomes and serve multiple customers and pipelines. The firm is not interested in traditional assets. 

The firm prefers to take a board seat however, it is not required. 

 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A private investment group in South Carolina invests in two verticals, healthcare and advanced computing. The firm primarily invests in medical devices (60%), as well as diagnostics (20%), life science tools (10%), and AI-based drug discovery platforms (10%). The firm invests in seed-Series A, investing between $1-5M in companies that have a validated prototype and have a defined regulatory path. The firm invests primarily in US-based companies but will invest in Israel and Europe.

The firm invests primarily in medical devices, with some investments in diagnostics as well. In terms of medical devices, the firm will invest in class II and class III devices, investing either just before, during or after FDA approval for class II devices, and in devices that have received IDE approval for class III devices. For AI-based companies, the firm is interested in technologies such as drug discovery. 

The firm can lead, co-invest or act as the sole investor. The firm takes a board seat with any company in which they invest. The firm will only invest in companies with validated prototypes and will not invest pre-company formation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A Norway-based coalition that partners between public, private, philanthropic, and civil organizations is currently investing in new platform technologies for rapid vaccine research and development and other interventions for pandemics and endemics. The organization is currently investing from their current 5-year plan. The organization is stage agnostic with typical check size being flexible but ranging from $1-100M USD. The organization is open to any geographic regions but is looking to invest in the global south in particular. Investments are typically made through non-dilutive funding but can explore other funding opportunities including equity. 

The organization invests in the infectious disease space whether that be vaccines, MABs, or other pandemic-preventing interventions; generally speaking, biotech companies in pandemic-related indications. It is unlikely that the organization would look at diagnostics, devices or digital health unless there was a very specific pandemic-preparedness value proposition. The organization is stage-agnostic and will typically meet with companies from pre-clinical stages to Phase II.  

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A USA-based firm with multiple billion dollars of assets under management, invests from its latest fund that closed in 2023. The firm makes investments in the form of equity (preferred stock) and is an activist investor; the firm prefers to lead investments, take a board seat at its portfolio companies and be actively involved in company management. The firm plans to make 6-8 new investments in life science companies per year. 

The firm invests in biopharmaceuticals and typically makes initial investments of $5-15m, with the potential for a total investment of $15-40m.  The fund invests in companies based globally, with a focus on North America or Europe. 
 
The firm invests exclusively in therapeutics.  The firm will consider opportunities in any indication area but generally does not invest in cardiovascular disorders, diabetes, or other acute chronic care fields. The firm is particularly interested in oncology, specialty drugs, orphan drugs, and other areas where there is a defined clinical path to move the asset toward approval.  While the firm usually only invests in assets in Phase II or Phase III, the firm may consider earlier opportunities in oncology, ophthalmology, dermatology, and infectious diseases.  The firm is open to working with companies in any area of therapeutic technology but is particularly interested in biologics, and has also invested in biosimilars.   

In addition to investing in existing companies, this fund also invests in spinouts (typically from pharma companies); for spinouts, Phase II or earlier products are more likely to be considered as the pharma companies are typically able to provide a significant amount of trial data. 
 
The firm prefers to back management teams that have worked together before; it’s preferred that the team have experience of launching products, and have worked in both small and large biotech companies.  While experience is an important consideration, the firm has also worked with first-time CEOs.  For investments other than spinouts, the firm prefers to work with privately-held companies but also has past experience of PIPEs. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
 

A global leading IVD (in vitro diagnostics) company has its main business in hematology, hematosis, urinalysis, immunochemistry, and clinical chemistry with over $3B in net sales. Regarding their Digital Healthcare Section, the office is in the Bay Area in Northern California and is scouting for opportunities in North America, from startups to co-development and co-investment, to compliment the firm’s internal product portfolio (e.g. blood biomarkers) and expand their digital healthcare business. Equity investments are made on a case-by-case basis, but when applicable, the corporation is looking for companies generally in Series A and B rounds with typical check size ranging from $1-10M USD. The corporation will also provide commercialization support in Japan and overseas markets. 
 
The firm is currently looking for companies that strategically align with their main business as well as (1) finding digital technologies that can assist with patient stratification and early risk identification to increase testing volume on the firm’s IVD tests (early identification), (2) digital therapeutics that can increase the value of diagnostics, and (3) enter new areas of homecare by utilizing blood biomarker assets and digital solutions. Subsectors include, but are not limited to, digital health, home care, digital therapeutics, digital biomarkers, and clinical decision support. Companies should typically be conducting clinical trials however, pre-clinical stages may be of considered. Interested indications are CNS diseases, cardiovascular diseases, lifestyle diseases (e.g. hypertension), mental health, and chronic kidney diseases. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.